Epsilen Bio’s mission is to develop transformative therapies for patients affected by underserved medical conditions, through stable epigenetic silencing of genes involved in pathological processes.
Several human diseases are associated to expression of mutated or pathogen-associated genes. These include life threatening or debilitating inherited genetic diseases, cancer, autoimmune diseases, degenerative diseases and even viral infections.
The approach developed by Epsilen Bio enables specific and stable silencing of the disease-associated gene, through inheritable epigenetic modifications. The technology thereby differs from transient silencing approaches that necessitate repeated life-long treatments for the patients, as well as from DNA sequence-modifying approaches in that Epsilen Bio’s approach does not alter the genetic code.
In collaboration with the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) that developed the technology and pioneered the field of Engineered Transcriptional Repressors (ETRs), Epsilen Bio now aims at bringing this scientific innovation to the patient’s bedside.